These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14571079)

  • 1. Repigmentation of vitiligo with pimecrolimus cream: a case report.
    Mayoral FA; Gonzalez C; Shah NS; Arciniegas C
    Dermatology; 2003; 207(3):322-3. PubMed ID: 14571079
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo.
    Mayoral FA; Vega JM; Stavisky H; McCormick CL; Parneix-Spake A
    J Drugs Dermatol; 2007 May; 6(5):517-21. PubMed ID: 17679186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.
    Köse O; Arca E; Kurumlu Z
    J Dermatolog Treat; 2010 May; 21(3):133-9. PubMed ID: 20394489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimecrolimus cream in repigmentation of vitiligo.
    Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
    Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topical calcineurin inhibitors in vitiligo.
    Wong R; Lin AN
    Int J Dermatol; 2013 Apr; 52(4):491-6. PubMed ID: 23331250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent onset vitiligo treated with systemic corticosteroid and topical tacrolimus: Need for early treatment in vitiligo.
    Lee DY; Kim CR; Lee JH; Yang JM
    J Dermatol; 2010 Dec; 37(12):1057-9. PubMed ID: 21083711
    [No Abstract]   [Full Text] [Related]  

  • 10. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
    Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
    Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
    Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
    J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
    Hartmann A; Bröcker EB; Hamm H
    J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band.
    Castanedo-Cazares JP; Lepe V; Moncada B
    Photodermatol Photoimmunol Photomed; 2003 Feb; 19(1):35-6. PubMed ID: 12713553
    [No Abstract]   [Full Text] [Related]  

  • 14. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
    Firooz A; Solhpour A; Gorouhi F; Daneshpazhooh M; Balighi K; Farsinejad K; Rashighi-Firoozabadi M; Dowlati Y
    Arch Dermatol; 2006 Aug; 142(8):1066-7. PubMed ID: 16924062
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.
    Farajzadeh S; Daraei Z; Esfandiarpour I; Hosseini SH
    Pediatr Dermatol; 2009; 26(3):286-91. PubMed ID: 19706089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trichomegaly induced by topical tacrolimus for the treatment of periorbital vitiligo: A brief report of a new adverse effect.
    Molés-Poveda P; Cowen EW
    Pediatr Dermatol; 2019 Jul; 36(4):e95-e96. PubMed ID: 31070265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
    Tanghetti EA
    Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical tacrolimus for treatment of childhood vitiligo in Asians.
    Kanwar AJ; Dogra S; Parsad D
    Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review.
    Scheinfeld N
    Dermatol Online J; 2004 Jul; 10(1):3. PubMed ID: 15347485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study.
    Barikbin B; Givrad S; Yousefi M; Eskandari F
    Clin Exp Dermatol; 2009 Oct; 34(7):776-80. PubMed ID: 19456797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.